ASTOLFI, Monica
 Distribuzione geografica
Continente #
NA - Nord America 997
EU - Europa 917
AS - Asia 359
AF - Africa 15
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.289
Nazione #
US - Stati Uniti d'America 982
DE - Germania 222
CN - Cina 202
AT - Austria 141
SE - Svezia 135
IE - Irlanda 93
UA - Ucraina 78
FR - Francia 61
FI - Finlandia 57
IT - Italia 55
KR - Corea 55
SG - Singapore 54
PL - Polonia 25
GB - Regno Unito 23
JP - Giappone 20
CA - Canada 15
SN - Senegal 14
SA - Arabia Saudita 12
GR - Grecia 10
VN - Vietnam 8
BE - Belgio 7
IN - India 5
RU - Federazione Russa 5
BG - Bulgaria 2
BY - Bielorussia 1
DK - Danimarca 1
EU - Europa 1
ID - Indonesia 1
PT - Portogallo 1
SC - Seychelles 1
TR - Turchia 1
UZ - Uzbekistan 1
Totale 2.289
Città #
Chandler 217
Beijing 173
Vienna 141
Dublin 93
Jacksonville 70
Dearborn 55
Nyköping 44
Villeurbanne 42
Medford 40
Singapore 38
Ashburn 36
Princeton 33
San Mateo 33
Houston 27
Norwalk 26
Warsaw 25
Ann Arbor 22
Wilmington 17
Fremont 15
Torino 14
Boardman 13
Toronto 13
Milan 11
Nürnberg 8
Boston 7
Brussels 7
Düsseldorf 7
Verona 7
Dong Ket 5
Guangzhou 4
Mcallen 4
Mountain View 4
Munich 4
Nanjing 4
New York 4
Washington 4
Fairfield 3
Falls Church 3
Hefei 3
Pune 3
Redwood City 3
Saint Petersburg 3
Turin 3
Woodbridge 3
Bologna 2
Costa Mesa 2
Florence 2
Hebei 2
Jinan 2
Kharkiv 2
Kunming 2
Leawood 2
Los Angeles 2
Nanchang 2
Novara 2
Santa Clara 2
Seattle 2
Sofia 2
Baotou 1
Belleville 1
Bengaluru 1
Berlin 1
Brook Park 1
Brownsville 1
Cedar Knolls 1
Changsha 1
Chieri 1
Copenhagen 1
Des Moines 1
Frankfurt am Main 1
Guildford 1
Hanover 1
Jinhua 1
Lisbon 1
London 1
Mahé 1
Marseille 1
Merzig 1
Miami 1
Michigan City 1
Odesa 1
Ottawa 1
Palm Bay 1
Quzhou 1
Redmond 1
San Francisco 1
San Jose 1
Shelby 1
Shenyang 1
Taizhou 1
Vancouver 1
Totale 1.352
Nome #
Long-Term Outcome of High-Dose Sequential Chemotherapy with Autografting (i-HDS) in Follicular Lymphoma at Diagnosis: An Update of the Prospective Multicenter Consecutive Trial of the "Gruppo Italiano Trapianto Di Midollo Osseo" (Gitmo) 144
Telomere Length Identifies Two Distinct Populations with Different Outcome among VH-Unmutated CLL Patients 107
Cyclooxygenase-2 (COX-2) Is Frequently Expressed in Multiple Myeloma (MM) and Is Associated with Poor Outcome 106
12p, 1p, 1q, 5q, 11q ABNORMALITIES AND IMMUNOPHENOTYPE IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE, MULTIPLE MYELOMA AND PLASMA CELL LEUKEMIA. 103
Long-Term Monitoring of Cancer-Free Subjects Carrying Non-Lymphoma Associated bcl2/IgH Rearrangements (NLABR): Prolonged Persistence of Clonal Populations Potentially Related to Follicular Lymphoma (FL) 102
Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations 99
Sequential Brief Chemo-Immunotherapy FND + Rituximab in Elderly Patients with Advanced Stage Follicular Lymphoma (FL): High Clinical and Molecular Remission Rate Associated with a Prolonged Failure-Free Survival 95
Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes 92
Immunoglobulin (Ig) Repertoire in Multiple Myeloma: High Frequency of Recurrent Aminoacid Substitutions in the FR2 and CDR2 91
Immunophenotypic profile and cytogenetic aberrations detected by interphase FISH in B-CLL patients 89
A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. 85
Telomerase Inhibitor BIBR1532 Induces Telomere Shortening and Growth Inhibition in Extra-Germinal Center (GC)-Derived Lymphoid Cell Lines 84
MOLECULAR REMISSION IN A MULTIPLE MYELOMA PATIENT AFTER A NON MYELOABLATIVE ALLOGENEIC TRANSPLANT: PROOF OF PRINCIPLE 84
Central nervous system relapse in a patient with mantle cell lymphoma in continuous clinical and molecular remission at six years since autografting. 82
Qualitative and Quantitative Molecular Follow up of Minimal Residual Disease after Non Myeloablative Allografting for Multiple Myeloma. 82
REAL TIME PCR IN MULTIPLE MYELOMA: QUANTITATIVE ANALYSIS OF TUMOR CONTAMINATION OF STEM CELL HARVESTS 78
Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. 78
Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma. 77
Consolidation with Bortezomib, Thalidomide and Dexamethasone Induces Molecular Remissions in Autografted Multiple Myeloma Patients 77
Molecular monitoring of minimal residual disease after non-myeloablative allografting for multiple myeloma 74
Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders 73
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma 72
Impact of Early Consolidation with Bortezomib, Thalidomide and Dexamethasone on Molecularly-Detectable Disease in MM Patients in CR or VGPR Following Autologous Transplantation: Uncommon Achievement of Molecular Remission Despite Evidence of Tumor Load Reduction by Real Time PCR 65
PCR-detectable non-neoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis, but rare in subjects treated with chemotherapy. 64
Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. 62
REAL TIME QUANTITATIVE PCR SHOWS THAT PERIPHERAK BLOOD STEM CELL (PBPC) HARVESTS ARE SIGNIFICANTILY LESS CONTAMINATED THAN BONE MARROW (BM) IN MULTIPLE MYELOMA PATIENTS (MM). 55
Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer 52
Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. 52
Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in myeloma 51
Totale 2.375
Categoria #
all - tutte 7.010
article - articoli 0
book - libri 0
conference - conferenze 3.918
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.928


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020221 0 0 9 33 12 55 36 7 13 18 26 12
2020/2021217 30 10 10 9 21 10 13 9 33 34 21 17
2021/2022340 0 6 7 22 6 5 79 12 5 31 82 85
2022/2023518 54 47 13 62 48 128 35 37 53 11 22 8
2023/2024175 26 54 12 7 8 29 3 3 0 6 2 25
2024/202536 0 12 24 0 0 0 0 0 0 0 0 0
Totale 2.375